These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Improving patient-reported measures in oncology: a payer call to action. Schmidt T; Valuck T; Perkins B; Riposo J; Patel P; Westrich K; Basch E; McClellan M J Manag Care Spec Pharm; 2021 Jan; 27(1):118-126. PubMed ID: 33103618 [TBL] [Abstract][Full Text] [Related]
4. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
5. The Inclusion of Economic Endpoints as Outcomes in Clinical Trials Reported to ClinicalTrials.gov. Mitchell JM; Patterson JA J Manag Care Spec Pharm; 2020 Apr; 26(4):386-393. PubMed ID: 32223593 [TBL] [Abstract][Full Text] [Related]
6. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. Hung A; Slejko JF; Lugo A; Shaya F; Haines ST; Mullins CD J Manag Care Spec Pharm; 2019 Aug; 25(8):913-921. PubMed ID: 31347981 [TBL] [Abstract][Full Text] [Related]
7. Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. Chambers JD; Pope EF; Wilkinson CL; Neumann PJ J Manag Care Spec Pharm; 2018 Dec; 24(12):1240-1246. PubMed ID: 30479201 [TBL] [Abstract][Full Text] [Related]
8. Modeling the Budgetary Impact of Payer Utilization Management Strategies: An Adapted Framework Based on Lessons Learned. Hung A; Lugo A; Mullins CD J Manag Care Spec Pharm; 2019 Aug; 25(8):922-926. PubMed ID: 31347978 [TBL] [Abstract][Full Text] [Related]
9. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P; Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364 [TBL] [Abstract][Full Text] [Related]
10. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers? Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082 [TBL] [Abstract][Full Text] [Related]
11. Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze). Maheshwari A; Bell JL; Bhide P; Brison D; Child T; Chong HY; Cheong Y; Cole C; Coomarasamy A; Cutting R; Hardy P; Hamoda H; Juszczak E; Khalaf Y; Kurinczuk JJ; Lavery S; Linsell L; Macklon N; Mathur R; Pundir J; Raine-Fenning N; Rajkohwa M; Scotland G; Stanbury K; Troup S; Bhattacharya S Hum Reprod; 2022 Mar; 37(3):476-487. PubMed ID: 34999830 [TBL] [Abstract][Full Text] [Related]
12. The adoption of pharmaceutical innovation and its impact on the treatment costs for Alzheimer's disease in Taiwan. Lo TF; Hsieh CR J Ment Health Policy Econ; 2014 Sep; 17(3):107-17. PubMed ID: 25543114 [TBL] [Abstract][Full Text] [Related]
13. Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis. Bloudek LM; Pandey R; Fazioli K; Ollendorf DA; Carlson JJ J Manag Care Spec Pharm; 2021 Aug; 27(8):1046-1055. PubMed ID: 34337994 [No Abstract] [Full Text] [Related]
14. Review of Acute Treatment of Migraine Trial Results With the New FDA Endpoints: Design Implications for Future Trials. Hindiyeh NA; Kellerman DJ; Schmidt PC Headache; 2019 May; 59(5):819-824. PubMed ID: 30953576 [TBL] [Abstract][Full Text] [Related]
16. Current and evolving treatment strategies for the Alzheimer disease continuum. Marasco RA Am J Manag Care; 2020 Aug; 26(8 Suppl):S167-S176. PubMed ID: 32840330 [TBL] [Abstract][Full Text] [Related]
17. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD. Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385 [TBL] [Abstract][Full Text] [Related]
18. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]